A Randomized, Positive-controlled, Multicenter, Phase II Study of Anlotinib (AL3818) Hydrochloric Capsule in Patients With Advanced Renal Cell Carcinoma (RCC)
Status: Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 02 Jan 2019
Price : $35 *
At a glance
- Drugs Anlotinib (Primary) ; Sunitinib
- Indications Renal cell carcinoma
- Focus Therapeutic Use
- Sponsors Chia Tai Tianqing Pharmaceutical Group
- 25 Apr 2016 Planned number of patients changed from 180 to 133.
- 25 Apr 2016 Planned End Date changed from 1 Dec 2015 to 1 Dec 2016.
- 25 Apr 2016 Planned primary completion date changed from 1 Dec 2015 to 1 Dec 2016.